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for malignant pleural mesothelioma: a case report
Yoshinori Yamashita1*, Hiroaki Harada1, Hidenori Mukaida2 and Mayumi Kaneko3Abstract
We report a case of a 58-year-old Japanese man with epithelioid-type MPM, with a left chest wall protruding tumor,
who underwent extrapleural pneumonectomy and chest wall resection. Postsurgical pathology showed that surgical
margins were free of mesothelioma cells. Positron emission tomography taken 5 years after surgery showed no
recurrence at any site, suggesting that long-term survival could be dependent on margin-free tumor resection or
that specific MPM subgroups have lower malignant potential, leading to improved survival.
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Chemotherapy, immunotherapy, irradiation, hyperther-
mia, and surgery have all been applied for malignant
pleural mesothelioma (MPM); however, presently, with
the exception of surgery, the outcomes of these treat-
ments are unsatisfactory. The benefit of extrapleural
pneumonectomy (EPP) for MPM has been controversial
since data from the MARS feasibility trial were pub-
lished [1]. However, in three phase 2 trials of EPP, as
part of trimodality treatment, 50–71% of patients com-
pleted the planned treatment [2]. Many chest surgeons
consider clinical T1-2 N0 disease to be an indication for
EPP, although this is not widely propounded because of
the malignant potential of MPM and the surgical stress
associated with EPP. Here, we report the case of a pa-
tient with stage III MPM who experienced long-term
survival after radical EPP with simultaneous chest wall
resection.Case presentation
A 58-year-old Japanese man was admitted with left chest
pain. He worked in the electrical industry for 40 years.
Chest radiography revealed left pleural effusion and a 6-cm
diameter protruding tumor on the anterior chest wall. A
needle biopsy pathologically confirmed epithelioid-type
MPM. Computed tomography revealed direct intercostal* Correspondence: yamashitay@kure-nh.go.jp
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article, unless otherwise stated.invasion of mesothelioma between the first two ribs
(Figure 1). Preoperative OK-432 (Picibanil™, Chugai Pharm.
Co. Ltd., Tokyo, Japan) was administered twice (total 3KE)
intrathoracically to promote adhesion between the visceral
and the parietal pleura. We decided to perform EPP on
consultation with the patient, following a diagnosis of clin-
ical T3N0M0 stage III MPM based on the International
Mesothelioma Interest Group classification.
Two weeks after OK-432 infusion, EPP plus mediastinal
lymph node dissection, combined with chest wall resec-
tion, including the first two ribs, the pericardium, and the
diaphragm, was performed via a sigmoid incision of the
fifth intercostal space. The pericardium and the dia-
phragm were reconstructed using polytetrafluoroethylene
Blood loss and the duration of surgery were 1085 g and
490 minutes, respectively. Histological analysis showed
that, the mesothelioma cells reached the fascia of the
major pectoral muscle invading the intercostal muscles
and partially destroying the ribs. However, pathological
investigation confirmed that all the surgical margins were
tumor-free. In addition, microscopic findings showed
the aggregation of inflammatory cells, lymphocytes, plasma
cells, and histiocytes with the mesothelioma cells (Figure 2).
Postoperative immunohistochemical analysis confirmed the
diagnosis of epithelioid-type MPM. Mesothelioma cells
stained positive for calretinin, D2-40, CAM5.2, vimentin,
and myoglobin, but were negative for PE-10, TTF-1, and
CEA. The Ki67 and p53 labeling indices of the mesotheli-
oma cells were 30–40% and 10%, respectively.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Preoperative chest computed tomography findings after the drainage of effusion. A chest wall tumor invading the space
between the first and second ribs.
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apy and radiation therapy, although this was recom-
mended. The patient has resumed his daily routine and
has been followed-up for 64 months. The most recent
positron emission tomography scan revealed no postsur-
gical recurrence at any site for >5 years (Figure 3).a
b
Figure 2 Histopathological and immunohistochemical examination of
mesothelioma. a. Hematoxylin and eosin staining at the site of chest inva
b. Calretinin positivity. c. D2-40 positivity. d. Thyroid transcription factor-1 nDiscussion
The histological and immunohistochemical findings pre-
sented here undoubtedly revealed epithelioid-type MPM.
Although the reason for the aggregation of inflammatory
cells was unknown, this was presumed to be attributable
to OK-432 infusion into the thoracic cavity beforec
d
the resected tumor revealed epithelioid-type malignant pleural
sion shows malignant pleural mesothelioma and inflammatory cells.
egativity.
Figure 3 A positron emission tomography scan shows that the patient remains recurrence free 5 years after extrapleural pneumonectomy.
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stress caused by EPP, pleurectomy and decortication (P/D)
has been suggested as a more feasible alternative that
would confer substantial survival benefit. Lang-Lazdunski
et al. [3] reported that P/D combined with hyperthermic
pleural lavage with povidone-iodine and adjuvant chemo-
therapy was well tolerated and associated with low mor-
bidity and mortality. On the other hand, retrospective
analysis of the International Association for the Study of
Lung Cancer Mesothelioma database showed no differ-
ence in the median survival time between EPP and P/D,
except in stage I patients, in whom EPP conferred a sub-
stantial survival benefit [4].
Some reports indicated that trimodality improves
long-term survival [2]. However, there are examples
in the literature of long-term survival in the absence
of trimodal treatment [5-7]. There are 3 possibilities
for long term-survival here. First, tumor cell-free
clean surgical margins is essential for a good progno-
sis. Therefore, a successful curative surgery should be
based on careful evaluation of the surgical margins.
Here, 36 paraffin-embedded blocks of the pathological spe-
cimen were examined, all of which revealed surgical mar-
gins free from mesothelioma cells, including those taken
from the pericardium, diaphragm, and chest wall. Second,
the pathological diagnosis of MPM is not consistent and
the classification of mesothelioma is heterogeneous. Some
subgroups of patients with MPM may have a good progno-
sis [5-7]. It is desirable that an exact diagnosis and classifi-
cation of mesothelioma should be established to predict
long-term prognosis. This essential information would be
invaluable for determining the optimal surgical indication
and for patient selection, especially for EPP. Third, OK-432
helps to promote adhesion between the visceral pleura and
the parietal pleura. This adhesion prevents leakage ofpleural effusion in the event that the visceral pleura is acci-
dentally opened during EPP. However, OK-432 promotes
the aggregation of lymphocytes, which could exhibit antitu-
mor effects [8].
Conclusion
The patient here demonstrates long-term, recurrence-free
survival following EPP, with combined resection of a chest
wall-invading T3 tumor, for MPM. Our case findings sug-
gest that long-term survival could be dependent on margin-
free tumor resection and that even in advanced cases, some
patients with a subgroup of MPM that has lower malignant
potential may have a better prognosis than others.
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